Company: TELO
Filing Date: 2025-07-22
Form Type: 8-K
Source: 0001641172-25-020563
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-07-22
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

On
July 18, 2025, Telomir Pharmaceuticals, Inc. (the “ Company”), sold a total of 1,100,000 shares of its common stock, no par
value, in block sales to institutional investors, at an average price of $2.6045 per share (a premium to the prior day’s close),
through its at-the-market equity offering facility (the “ Offering”). Gross proceeds from the Offering totaled approximately
$2.9 million, prior to deducting fees and expenses. The trades for the Offering were facilitated through Rodman & Renshaw, via the
StockBlock platform. The Offering did not include any warrants.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                     TELOMIR                                       
  Dated:             By:                        /s/                
                     Name:                      Erez               
                     Title:                     Chief